v3.25.2
BUSINESS SEGMENT INFORMATION (Tables)
 9 Months Ended
Jun. 30, 2025
BUSINESS SEGMENT INFORMATION [Abstract]  
Segment Reporting Information by Segment
The following tables present selected financial information about the Company’s reportable segments and Corporate for the purpose of reconciling to the consolidated totals for the three and nine months ended June 30, 2025 (in thousands):
 
                     
For the three months ended June 30, 2025   Consolidated    Logistics    Life Sciences    Manufacturing    Corporate 
Revenues
  $49,145   $43,231   $3,490   $2,424   $ — 
Forwarding expenses and cost of revenues
   33,035    31,259    624    1,152      — 
Gross profit
   16,110    11,972    2,866    1,272      — 
Selling, general and administrative
   13,525    9,434    2,062    764    1,265 
Amortization of intangible assets
   654      —       —       —     654 
Income (loss) from operations
   1,931    2,538    804    508    (1,919) 
Interest expense
   442    289    73    80      — 
Identifiable assets
   126,032    52,255    13,349    4,453    55,975 
Capital expenditures, net of disposals
   69    5    45    19      — 
 
                     
                     
                     
For the nine months ended June 30, 2025
    Consolidated      Logistics      Life Sciences      Manufacturing      Corporate  
Revenues
  $151,230   $133,361   $10,639   $7,230   $ — 
Forwarding expenses and cost of revenues
   103,407    98,155    1,870    3,382      — 
Gross profit
   47,823    35,206    8,769    3,848      — 
Selling, general and administrative
   40,576    28,327    5,979    2,507    3,763 
Amortization of intangible assets
   1,937      —       —       —     1,937 
Income (loss) from operations
   5,310    6,879    2,790    1,341    (5,700) 
Interest expense
   1,668    1,168    280    220      — 
Identifiable assets
   126,032    52,255    13,349    4,453    55,975 
Capital expenditures, net of disposals   396    31    346    19    — 
 
The following tables present selected financial information about the Company’s reportable segments and Corporate for the purpose of reconciling to the consolidated totals for the three and nine months ended June 30, 2024 (in thousands):
 
                     
For the three months ended June 30, 2024
   Consolidated      Logistics      Life Sciences      Manufacturing      Corporate  
Revenues
  46,724   $40,677   $3,208   $2,839   $— 
Forwarding expenses and cost of revenues
  31,633    29,725    609    1,299     — 
Gross profit
  15,091    10,952    2,599    1,540      — 
Selling, general and administrative
  13,358    9,444    1,812    793    1,309 
Amortization of intangible assets
  555      —       —       —     555 
Income (loss) from operations
  1,178    1,508    787    747    (1,864) 
Interest expense
  589    426    97    66      — 
Identifiable assets
  108,566    42,025    12,075    4,374    50,092 
Capital expenditures, net of disposals
  331    21    302    8      —  
 
                     
For the nine months ended June 30, 2024
    Consolidated      Logistics      Life Sciences      Manufacturing      Corporate  
Revenues
  $129,881   $111,991   $10,213   $7,677   $ — 
Forwarding expenses and cost of revenues
   86,822    81,232    2,065    3,525      — 
Gross profit
   43,059    30,759    8,148    4,152      — 
Selling, general and administrative
   38,664    27,186    5,307    2,364    3,807 
Amortization of intangible assets
   1,635      —       —       —     1,635 
Income (loss) from operations
   2,760    3,573    2,841    1,788    (5,442) 
Interest expense
   1,663    1,188    245    230      — 
Identifiable assets
   108,566    42,025    12,075    4,374    50,092 
Capital expenditures, net of disposals
   658    47    603    8      —